Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan Sells 1,514,100 Shares

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Director Andrew Regan sold 1,514,100 shares of the company’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $0.26, for a total transaction of $393,666.00. Following the sale, the director now owns 177,627 shares of the company’s stock, valued at $46,183.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Andrew Regan also recently made the following trade(s):

• On Monday, July 15th, Andrew Regan sold 1,005,200 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total value of $251,300.00.
• On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.25, for a total value of $347,455.00.
• On Wednesday, July 10th, Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.33, for a total value of $49,500.00.
• On Monday, July 8th, Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.51, for a total transaction of $18,320.73.
• On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.64, for a total transaction of $640.00.

Conduit Pharmaceuticals Stock Performance

NASDAQ:CDT opened at $0.13 on Friday. Conduit Pharmaceuticals Inc. has a twelve month low of $0.11 and a twelve month high of $22.00. The firm’s fifty day simple moving average is $0.18 and its 200 day simple moving average is $1.78.

Conduit Pharmaceuticals (NASDAQ:CDT) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Conduit Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.